XTL Biopharmaceutica Number Of Shares Shorted vs. Net Income

XTLB Stock  USD 2.07  0.03  1.43%   
Based on the key profitability measurements obtained from XTL Biopharmaceutica's financial statements, XTL Biopharmaceuticals Ltd may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess XTL Biopharmaceutica's ability to earn profits and add value for shareholders. The current year's Sales General And Administrative To Revenue is expected to grow to 1.68, whereas Price To Sales Ratio is forecasted to decline to 0.15. At present, XTL Biopharmaceutica's Accumulated Other Comprehensive Income is projected to increase significantly based on the last few years of reporting. The current year's Change To Netincome is expected to grow to about 422.4 K, whereas Operating Income is forecasted to decline to (803.2 K).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.430.62
Way Down
Slightly volatile
For XTL Biopharmaceutica profitability analysis, we use financial ratios and fundamental drivers that measure the ability of XTL Biopharmaceutica to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well XTL Biopharmaceuticals Ltd utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between XTL Biopharmaceutica's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of XTL Biopharmaceuticals Ltd over time as well as its relative position and ranking within its peers.
  
Check out Your Current Watchlist.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.76)
Earnings Share
(0.03)
Return On Assets
(0.14)
Return On Equity
(0.13)
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

XTL Biopharmaceuticals Net Income vs. Number Of Shares Shorted Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining XTL Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare XTL Biopharmaceutica value to that of its competitors to determine the firm's financial worth.
XTL Biopharmaceuticals Ltd is rated third in number of shares shorted category among its peers. It is rated first in net income category among its peers . At present, XTL Biopharmaceutica's Net Loss is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the XTL Biopharmaceutica's earnings, one of the primary drivers of an investment's value.

XTL Net Income vs. Number Of Shares Shorted

Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

XTL Biopharmaceutica

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
70.82 K
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

XTL Biopharmaceutica

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(1.78 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.

XTL Net Income Comparison

XTL Biopharmaceutica is currently under evaluation in net income category among its peers.

XTL Biopharmaceutica Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in XTL Biopharmaceutica, profitability is also one of the essential criteria for including it into their portfolios because, without profit, XTL Biopharmaceutica will eventually generate negative long term returns. The profitability progress is the general direction of XTL Biopharmaceutica's change in net profit over the period of time. It can combine multiple indicators of XTL Biopharmaceutica, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income23 K24.1 K
Operating Income-765 K-803.2 K
Net Loss-1.8 M-1.9 M
Income Tax Expense-167.9 K-159.5 K
Income Before Tax-1.8 M-1.9 M
Total Other Income Expense Net-1 M-966.1 K
Net Loss-1.6 M-1.6 M
Net Loss-2.2 M-2.4 M
Interest Income46 K34.2 K
Net Interest Income-28 K-26.6 K
Change To Netincome402.3 K422.4 K
Income Quality 0.40  0.56 

XTL Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on XTL Biopharmaceutica. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of XTL Biopharmaceutica position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the XTL Biopharmaceutica's important profitability drivers and their relationship over time.

Use XTL Biopharmaceutica in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if XTL Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in XTL Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.

XTL Biopharmaceutica Pair Trading

XTL Biopharmaceuticals Ltd Pair Trading Analysis

The ability to find closely correlated positions to XTL Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace XTL Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back XTL Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling XTL Biopharmaceuticals Ltd to buy it.
The correlation of XTL Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as XTL Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if XTL Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for XTL Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your XTL Biopharmaceutica position

In addition to having XTL Biopharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small Cap ETFs Thematic Idea Now

Small Cap ETFs
Small Cap ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small Cap ETFs theme has 168 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Cap ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:
Check out Your Current Watchlist.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
To fully project XTL Biopharmaceutica's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of XTL Biopharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include XTL Biopharmaceutica's income statement, its balance sheet, and the statement of cash flows.
Potential XTL Biopharmaceutica investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although XTL Biopharmaceutica investors may work on each financial statement separately, they are all related. The changes in XTL Biopharmaceutica's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on XTL Biopharmaceutica's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.